Cocrystal Pharma (COCP) Cash & Current Investments (2010 - 2026)

Cocrystal Pharma (COCP) has 17 years of Cash & Current Investments data on file, last reported at $4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 31.62% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (down 31.62% YoY), and the FY2025 full-year result was $7.2 million, down 28.32% from the prior year.
• Cash & Current Investments fell to $4.8 million in Q1 2026, from $7.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $54.8 million in Q1 2022 to a low of $150000.0 in Q2 2022.
• A 5-year average of $16.3 million and a median of $10.0 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments tumbled 99.78% in 2022 and jumped 21562.67% in 2023, its largest moves.
• Tracing COCP's Cash & Current Investments over 5 years: stood at $37.3 million in 2022, then retreated by 28.93% to $26.5 million in 2023, then slumped by 62.23% to $10.0 million in 2024, then decreased by 28.32% to $7.2 million in 2025, then slumped by 32.61% to $4.8 million in 2026.
• Business Quant data shows COCP's Cash & Current Investments at $4.8 million in Q1 2026, $7.2 million in Q4 2025, and $7.9 million in Q3 2025.